2
Clinical Trials associated with Bevacizumab biosimilar(Eden Biologics, Inc.)An Exploratory Clinical Study of Radiotherapy Combined With Sintilimab Plus Bevacizumab Biosimilar in the Treatment of Unresectable Hepatocellular Carcinoma (uHCC) With Portal Vein Tumor Thrombus (PVTT)
This study was a prospective, single-arm, single-center, phase II exploratory clinical study. To investigate the efficacy and safety of radiotherapy combined with sintilimab and bevacizumab biosimilar in the treatment of unresectable hepatocellular carcinoma with portal vein tumor thrombus.
A Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
This is a Phase I, Double-blind, Randomized, Parallel-group, Single-dose, Three-Arm Study to Compare the Pharmacokinetics and to Evaluate the Tolerability, Safety and Immunogenicity of JHL1149 and Bevacizumab (Avastin) Sourced from the European Union (EU) and the Union States (US) in Healthy Male Volunteers
100 Clinical Results associated with Bevacizumab biosimilar(Eden Biologics, Inc.)
100 Translational Medicine associated with Bevacizumab biosimilar(Eden Biologics, Inc.)
100 Patents (Medical) associated with Bevacizumab biosimilar(Eden Biologics, Inc.)
100 Deals associated with Bevacizumab biosimilar(Eden Biologics, Inc.)